Neuromodulation Addiction Treatments Move Home
Neuromodulation can detect the early brain signals of craving to avert relapse.
Updated May 16, 2026 | Reviewed by Hara Estroff Marano
For much of modern psychiatry, the brain has been treated indirectly with medications altering neurotransmitters—serotonin, dopamine , norepinephrine—under the assumption that downstream effects will rebalance mood or drug cravings. Operating apart from dysfunction in the brain’s circuits, this approach has produced meaningful advances.
In contrast, neuromodulation directly targets the electrical activity of brain networks. And what began as a laboratory curiosity has evolved into a clinical treatment tool, moving from hospitals to offices and, now, to patient homes.
Modern noninvasive neuromodulation began in the 1980s with transcranial magnetic stimulation (TMS). The first device was developed in the early 1980s and sold as the Magstim Model 200. It was a revolutionary, noninvasive method for stimulating the brain and treating depression .
The key conceptual leap occurred in the 1990s through the work of neurologist and psychiatrist Mark George of the Medical University of South Carolina. Back then, neuroimaging studies revealed that brain patterns in depression: reduced activity in the left dorsolateral prefrontal cortex (DLPFC) and disrupted communication between the prefrontal and limbic regions. George wondered whether psychiatric disorders reflected dysfunctional activity in specific circuits and whether targeted stimulation could restore circuits to health.
Using repetitive TMS (rTMS), George’s group applied high-frequency stimulation to the left DLPFC, demonstrating antidepressant effects. The result reframed TMS from a diagnostic probe into a therapeutic intervention. It also helped establish “circuit psychiatry”—the idea that mental disorders are also disorders of network dynamics.
Neuromodulation in Addiction Medicine
In 2014, the U.S. Food and Drug Administration cleared the electroauricular device (EAD) the NSS-2 Bridge Neurostimulation System, an early translation of the concept, for use in acupuncture. Authorization expanded in 2017 to support reducing opioid withdrawal symptoms. The Bridge is a small, disposable, battery-powered device worn behind the ear for five days during acute withdrawal. It delivers continuous electrical stimulation to auricular branches of cranial nerves. The Bridge provides continuous, automated stimulation in an ambulatory setting, enabling a drug-free, home-based intervention during early opioid withdrawal, when relapse risk is highest.
Another device, the Sparrow Therapy System, cleared by the FDA in 2021, delivers transcutaneous auricular neurostimulation (tAN) without percutaneous electrodes. This device is useful in facilitating transition to medications for opioid use disorder, such as extended-release naltrexone (Vivitrol), which requires opioid abstinence prior to initiation. By attenuating withdrawal severity, auricular neurostimulation may reduce relapse risk during this vulnerable interval.
Evolution of Neuromodulation Devices for Addiction Medicine
When brain networks are dysregulated, behavior becomes biased toward immediate rewards despite adverse consequences. Craving is not merely a subjective experience; it is also a circuit-level phenomenon. Repetitive transcranial magnetic stimulation targeting the DLPFC has been shown to reduce subjective craving, enhance inhibitory control, decrease responsiveness to drug-related cues and enhance restraint and decision-making .
A major milestone occurred in 2020, when the company BrainsWay received FDA clearance for a neuromodulatory device targeting smoking cessation—the first such device approved for an addictive disorder. The milestone validated that targeted modulation of neural circuits can produce clinically meaningful behavior changes. In the most recent study by the MUSC group, cigarette smokers who received high-frequency stimulation to the DLPFC – the brain’s “ self-control ” region – experienced a significantly greater reduction in cigarette use than in the reward-targeting or placebo conditions, averaging more than 11 cigarettes per day.
Emerging approaches integrate wearable, high-density EEG devices with adaptive neuromodulation systems that deliver stimulation in response to signals of early craving. This represents a shift toward personalized intervention—timing neuromodulation to the earliest detectable phases of relapse risk.
The Second Shift: Clinic to Home
Traditional TMS is effective but requires specialized equipment and repeated clinic visits; the field is shifting toward smaller, portable technologies designed for chronic conditions such as depression and addiction. Auricular devices set the stage for modern at-home neuromodulation. Devices using transcranial direct current stimulation (tDCS) offer modest but practical effects, enabling repeated use with minimal supervision. The transition became concrete in 2025, when Flow Neuroscience received FDA approval for its FL-100 device, a prescription-based, home treatment for major depression targeting the dorsolateral prefrontal cortex.
Neuromodulation, especially in portable form, opens the possibility of timing interventions in response to specific states or feelings, such as before high-risk situations, during early craving, or after exposure to triggers. This introduces new therapeutic possibilities for treating brain states in real time.
Relapse is often preceded by fast but predictable shifts in neural and physiological states. A portable neuromodulation device could intervene during this window. Neuromodulation may function best by enhancing the brain’s capacity to resist impulses, to engage with therapy, and to sustain recovery.
From Home Devices to Brain-Computer Interfaces
At-home neuromodulation is in its infancy. Wearable sensors, EEG systems, and machine learning are part of the process.
The most important emerging concept is the closed-loop system. In a closed-loop neuromodulation system, sensors detect physiological or neural signals ( stress , sleep disruption, EEG patterns). Algorithms identify patterns associated with risk states and the device automatically delivers neuromodulatory stimulation when most needed. This transforms neuromodulation into an adaptive system.
Such a system might detect early signs of craving, deliver targeted stimulation to the DLPFC, and reinforce executive control before relapse occurs. Early versions of closed-loop neuromodulation already exist in domains such as epilepsy and movement disorders.
Initially, the devices have been used for treatment-resistant depression, substance use disorders, anxiety , and insomnia . But the same circuits are involved in everyday functions such as attention , memory , decision-making, and emotional regulation . If stimulation could restore impaired function, it could also enhance function. For example, a fully-remote, phase-2 randomized trial supports the clinical potential of home-based neuromodulation.
In this study, a 10-week course of remotely supervised transcranial direct current stimulation (tDCS) produced significant improvements in depressive symptoms, with high levels of acceptability and safety. The trial demonstrated the feasibility of delivering neuromodulation outside traditional clinical settings, reinforcing a paradigm shift toward home-based supervised interventions. The findings suggest that neuromodulation can move beyond acute withdrawal management to modulate neural circuits implicated in mood, craving, and relapse vulnerability.
We are beginning to detect brain states such as craving. The real breakthrough will be in closed-loop systems that combine detection and modulation.
In the near term, neuromodulation will likely function as an adjunct, enhancing therapy, reducing relapse risk, and strengthening treatment engagement. In the longer term, as sensing and stimulation technologies integrate, it may become part of a continuous feedback system linking the brain, behavior, and environment.
What began with clinic-based magnetic stimulation has evolved toward increasingly individualized intervention. At-home neuromodulation represents growing acceptance that brain activity can be measured, targeted, and modulated. This progression lowers conceptual barriers to more advanced interfaces and positions neuromodulation as an expanding component of psychiatric and addiction treatment.
The next phase of neuromodulation in addiction will be defined by precision in timing. As high-density electroencephalography (EEG), wearable physiological sensors and machine learning converge, it is becoming increasingly feasible to identify individualized neural signatures of craving, stress, and relapse vulnerability in real time. Such signals evolve over minutes to hours, often preceding conscious awareness of craving itself.
High-density EEG and related modalities provide the input, adaptive algorithms define the state, and targeted stimulation delivers the output. The goal is not simply symptom reduction but stabilization of the neural systems governing decision-making and self-control.
Shifting addiction treatment from reactive to anticipatory . Rather than waiting for relapse, systems will detect early network-level changes—subtle alterations in frontal control, limbic reactivity, or salience processing—and intervene before behavior is expressed. Neuromodulation, delivered through portable or wearable devices, can be timed to high-risk states, reinforcing executive control or dampening maladaptive circuit activation precisely when needed.
An in-press Biological Psychiatry study by Liang-Jie-Cheng Huang and colleagues in China, strengthens the argument that neuromodulation may become a practical long-term treatment for addictions. Researchers randomized 55 patients with alcohol use disorder to active or sham continuous theta-burst stimulation (cTBS) targeting the right dorsolateral prefrontal cortex over two weeks. Over the following 12 months, the active-treatment group had a significantly lower risk of returning to baseline or heavier drinking.
The investigators linked clinical improvement to measurable changes in brain “craving networks.” Rather than simply changing activity in one isolated region, cTBS appeared to reduce abnormal connectivity between executive-control circuits and subcortical reward pathways—essentially weakening the neural coupling that helps sustain craving and compulsive alcohol seeking. If addiction neuromodulation works by reshaping dysfunctional brain networks rather than merely suppressing symptoms temporarily, home-based or portable stimulation technologies could eventually become part of ongoing relapse-prevention care, much as CPAP evolved from a lab-based intervention into a home therapy.
In the future, neuromodulation may become a tool not just for intervention but for craving reduction, helping guide the trajectory of neural activity toward recovery. There's a very exciting future ahead.
Oesterle TS, Bormann NL, Al-Soleiti M, Kung S, Singh B, McGinnis MT, Correa da Costa S, Rummans T, Chauhan M, Rojas Cabrera JM, Vettleson-Trutza SA, Scheitler KM, Shin H, Lee KH, Gold MS. Invasive and Non-Invasive Neuromodulation for the Treatment of Substance Use Disorders: A Review of Reviews. Brain Sci . 2025 Jul 6;15(7):723. doi: 10.3390/brainsci15070723. PMID: 40722314; PMCID: PMC12294003.
Li X, Caulfield KA, Carpenter MJ, Ramakrishnan V, Herrmann ES, Dancy M, George MS. DLPFC rTMS is more effective than sham or orbitofrontal stimulation for smoking cessation and alters frontal brain activity: A double-blind, sham-controlled randomized clinical trial. J Psychiatr Res. 2026 Jun;197:187-195. doi: 10.1016/j.jpsychires.2026.02.053. Epub 2026 Mar 4. PMID: 41793961; PMCID: PMC13020188.
Woodham RD, Selvaraj S, Lajmi N, Hobday H, Sheehan G, Ghazi-Noori AR, Lagerberg PJ, Rizvi M, Kwon SS, Orhii P, Maislin D, Hernandez L, Machado-Vieira R, Soares JC, Young AH, Fu CHY. Home-based transcranial direct current stimulation treatment for major depressive disorder: a fully remote phase 2 randomized sham-controlled trial. Nat Med . 2025 Jan;31(1):87-95. doi: 10.1038/s41591-024-03305-y. Epub 2024 Oct 21. PMID: 39433921; PMCID: PMC11750699.
Borrione L, Suen PJC, Razza LB, Santos LAD, Sudbrack-Oliveira P, Brunoni AR. The Flow brain stimulation headset for the treatment of depression: overview of its safety, efficacy and portable design. Expert Rev Med Devices . 2020 Sep;17(9):867-878. doi: 10.1080/17434440.2020.1813565. Epub 2020 Sep 7. PMID: 32820677.
Qu F, Zhang R. Transcutaneous electrical acupoint stimulation: a potential bridge linking traditional Chinese medicine and AI-driven transformation in modern healthcare. Integr Med Res . 2025 Sep;14(3):101221. doi: 10.1016/j.imr.2025.101221. Epub 2025 Aug 8. PMID: 40893422; PMCID: PMC12395463.
Ulett GA, Han S, Han JS. Electroacupuncture: mechanisms and clinical application. Biol Psychiatry . 1998 Jul 15;44(2):129-38. doi: 10.1016/s0006-3223(97)00394-6. PMID: 9646895.
Ding L, Li C, Zhang P, Chen C, Zhan J, Zeng J, Lu L. Acupuncture-related therapies for protracted opioid abstinence syndrome: A systematic review and meta-analysis. Integr Med Res . 2023 Sep;12(3):100976. doi: 10.1016/j.imr.2023.100976. Epub 2023 Jul 28. PMID: 37637184; PMCID: PMC10448024.
This article is part of the Bringwise Psychology Journal — daily insights on human behavior, mental health, and personal growth.